CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma

References

• Gandolfi S, Prada CP, Richardson PG. How I treat the young patient with multiple myeloma. Blood. 2018;132(11):1114–11. doi:10.1182/blood-2017-05-693606.
   PubMed Web of Science ®Google Scholar
• Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into the future. Haematologica. 2020;105:2358–2367. doi:10.3324/haematol.2020.247015.
   PubMed Web of Science ®Google Scholar
• Radocha J, van de Donk NWCJ, Weisel K. Monoclonal antibodies and antibody drug conjugates in multiple myeloma. Cancers (Basel). 2021;13:1–24. doi:10.3390/cancers13071571.
   Web of Science ®Google Scholar
• Verkleij CPM, Bruins WSC, Zweegman S, van de Donk NWCJ. Immunotherapy with antibodies in Multiple Myeloma: monoclonals. Bispecifics Immunoconjugates Hemato. 2021;2:116–130.
   Google Scholar
• Nooka AK, Weisel K, Van De Donk NWCJ, Routledge D, Otero PR, Song K, Quach H, Callander N, Minnema MC, Trudel S, et al. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. Future Oncol. 1987–2003;17:2021.
   Google Scholar
• Barilà G, Rizzi R, Zambello R, Musto P. Drug conjugated and bispecific antibodies for multiple myeloma: improving immunotherapies off the shelf. Pharmaceuticals. 2021;14(1):1–19. doi:10.3390/ph14010040.
   Web of Science ®Google Scholar
• Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19:589–608.
   PubMed Web of Science ®Google Scholar
• Wahl RL. Tositumomab and 131I therapy in non-Hodgkin’s lymphoma. J Nucl Med. 2005;46:128–140.
   PubMed Web of Science ®Google Scholar
• Ferrucci PF, Vanazzi A, Grana CM, Cremonesi M, Bartolomei M, Chinol M, Ferrari M, Radice D, Papi S, Martinelli G, et al. High activity 90Y-ibritumomab tiuxetan (Zevalin®) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. Br J Haematol. 2007;139:590–599. doi:10.1111/j.1365-2141.2007.06869.x.
   PubMed Web of Science ®Google Scholar
• Jovčevska I, Muyldermans S. The Therapeutic Potential of Nanobodies. BioDrugs. 2020;34(1):11–26. doi:10.1007/s40259-019-00392-z.
   PubMed Web of Science ®Google Scholar
• Ackaert C, Smiejkowska N, Xavier C, Sterckx YGJ, Denies S, Stijlemans B, Elkrim Y, Devoogdt N, Caveliers V, Lahoutte T, et al. Immunogenicity Risk Profile of Nanobodies. Front Immunol. 2021;12:632687. doi:10.3389/fimmu.2021.632687.
   PubMed Web of Science ®Google Scholar
• Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–797. doi:10.1146/annurev-biochem-063011-092449.
   PubMed Web of Science ®Google Scholar
• D’Huyvetter M, Xavier C, Caveliers V, Lahoutte T, Muyldermans S, Devoogdt N. Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer. Expert Opin Drug Deliv. 2014;11:1939–1954. doi:10.1517/17425247.2014.941803.
   PubMed Web of Science ®Google Scholar
• Dekempeneer Y, Keyaerts M, Krasniqi A, Puttemans J, Muyldermans S, Lahoutte T, D’huyvetter M, Devoogdt N. Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opin Biol Ther. 2016;16:1035–1047. doi:10.1080/14712598.2016.1185412.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14:2775–2784. doi:10.1158/1078-0432.CCR-07-4246.
   PubMed Web of Science ®Google Scholar
• Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev. 2003;194:196–206. doi:10.1034/j.1600-065X.2003.00035.x.
   PubMed Web of Science ®Google Scholar
• Vlummens P, De Veirman K, Menu E, De Bruyne E, Offner F, Vanderkerken K, Maes K. The use of murine models for studying mechanistic insights of genomic instability in multiple myeloma. Front Genet. 2019;10:1–11. doi:10.3389/fgene.2019.00740.
   PubMed Web of Science ®Google Scholar
• Lawson MA, McDonald MM, Kovacic N, Khoo WH, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA, et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 2015;6:1–15. doi:10.1038/ncomms9983.
   Web of Science ®Google Scholar
• Kassambara A, Rème T, Jourdan M, Fest T, Hose D, Tarte K, Klein B. GenomicScape: an easy-to-use web tool for gene expression data analysis. application to investigate the molecular events in the differentiation of B cells into plasma cells. PLoS Comput Biol. 2015;11:1–10. doi:10.1371/journal.pcbi.1004077.
   Web of Science ®Google Scholar
• Moreaux J, Hose D, Kassambara A, Reme T, Moine P, Requirand G, Goldschmidt H, Klein B. Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration. Blood. 2011;117:1280–1290. doi:10.1182/blood-2010-04-279760.
   PubMed Web of Science ®Google Scholar
• Pardon E, Laeremans T, Triest S, Rasmussen SGF, Wohlkönig A, Ruf A, Muyldermans S, Hol WGJ, Kobilka BK, Steyaert J. A general protocol for the generation of Nanobodies for structural biology. Nat Protoc. 2014;9:674–693. doi:10.1038/nprot.2014.039.
   PubMed Web of Science ®Google Scholar
• Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 1997;414(3):521-6. doi: 10.1016/S0014-5793(97)01062-4.
   Google Scholar
• Krasniqi A, D’Huyvetter M, Xavier C, Van Der Jeught K, Muyldermans S, Van Der Heyden J, Lahoutte T, Tavernier J, Devoogdt N. Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-hodgkin lymphoma. Mol Cancer Ther. 2017;16:2828–2839. doi:10.1158/1535-7163.MCT-17-0554.
   PubMed Web of Science ®Google Scholar
• Lemaire M, D’Huyvetter M, Lahoutte T, Van Valckenborgh E, Menu E, De Bruyne E, Kronenberger P, Wernery U, Muyldermans S, Devoogdt N, et al. Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies. Leukemia. 2014;28:444–447. doi:10.1038/leu.2013.292.
   PubMed Web of Science ®Google Scholar
• Xavier C, Devoogdt N, Hernot S, Vaneycken I, Huyvetter MD, De Vos J, Massa S, Lahoutte T, Caveliers V. Site-specific labeling of his-tagged Nanobodies with 99mTc: a practical guide. Methods Mol Biol. 2012;911:485-90. doi:10.1007/978-1-61779-968-6_30.
   Google Scholar
• Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131–137. doi:10.1162/153535003322556877.
   PubMedGoogle Scholar
• Rosset A, Spadola L, Ratib O. OsiriX: an open-source software for navigating in multidimensional DICOM images. J Digit Imaging. 2004;17:205–216. doi:10.1007/s10278-004-1014-6.
   PubMed Web of Science ®Google Scholar
• Dekempeneer Y, Caveliers V, Ooms M, Maertens D, Gysemans M, Lahoutte T, Xavier C, Lecocq Q, Maes K, Covens P, et al. Therapeutic efficacy of 213Bi-labeled sdAbs in a preclinical model of ovarian cancer. Mol Pharm. 2020;17:3553–3566. doi:10.1021/acs.molpharmaceut.0c00580.
   PubMed Web of Science ®Google Scholar
• D’Huyvetter M, Vincke C, Xavier C, Aerts A, Impens N, Baatout S, De Raeve H, Muyldermans S, Caveliers V, Devoogdt N, et al. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody. Theranostics. 2014;4:708–720. doi:10.7150/thno.8156.
   PubMed Web of Science ®Google Scholar
• Khoo WH, Ledergor G, Weiner A, Roden DL, Terry RL, McDonald MM, Chai RC, De Veirman K, Owen KL, Opperman KS, et al. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood. 2019;134:30–43. doi:10.1182/blood.2018880930.
   PubMed Web of Science ®Google Scholar
• De Veirman K, van Ginderachter JA, Lub S, de Beule N, Thielemans K, Bautmans I, Oyajobi BO, De Bruyne E, Menu E, Lemaire M, et al. Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells. Oncotarget. 2015;6:10532–10547. doi:10.18632/oncotarget.3300.
   PubMedGoogle Scholar
• Sia J, Szmyd R, Hau E, Gee HE. Molecular Mechanisms of Radiation-Induced Cancer Cell Death: a Primer. Front Cell Dev Biol. 2020;8:1–8. doi:10.3389/fcell.2020.00041.
   PubMed Web of Science ®Google Scholar
• Jagodinsky JC, Jin WJ, Bates AM, Hernandez R, Grudzinski JJ, Marsh IR, Chakravarty I, Arthur IS, Zangl LM, Brown RJ, et al. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy. Theranostics. 2021;11:6120–6137. doi:10.7150/thno.54881.
   PubMed Web of Science ®Google Scholar
• Pouget JP, Constanzo J. Revisiting the Radiobiology of Targeted Alpha Therapy. Front Med. 2021;8:1–11. doi:10.3389/fmed.2021.692436.
   Web of Science ®Google Scholar
• Minnix M, Adhikarla V, Caserta E, Poku E, Rockne R, Shively JE, Pichiorri F. Comparison of CD38-targeted α- versus β-radionuclide therapy of disseminated multiple myeloma in an animal model. J Nucl Med. 2021;62:795–801. doi:10.2967/jnumed.120.251983.
   PubMed Web of Science ®Google Scholar
• Fichou N, Gouard S, Maurel C, Barbet J, Ferrer L, Morgenstern A, Bruchertseifer F, Faivre-Chauvet A, Bigot-Corbel E, Davodeau F, et al. Single-dose anti-CD138 radioimmunotherapy: bismuth-213 is more efficient than lutetium-177 for treatment of multiple myeloma in a preclinical model. Front Med. 2015;2:76. doi:10.3389/fmed.2015.00076.
   Web of Science ®Google Scholar
• Puttemans J, Stijlemans B, Keyaerts M, Vander Meeren S, Renmans W, Fostier K, Debie P, Hanssens H, Rodak M, Pruszynski M, et al. The road to personalized myeloma medicine: patient-specific single-domain antibodies for anti-idiotypic radionuclide therapy. Mol Cancer Ther. 2021. doi:10.1158/1535-7163.MCT-21-0220.
   PubMed Web of Science ®Google Scholar
• Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, et al. Anti-CSl humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329–1337. doi:10.1182/blood-2007-08-107292.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–2463. doi:10.1200/JCO.2002.11.076.
   PubMed Web of Science ®Google Scholar
• Lecocq Q, De Vlaeminck Y, Hanssens H, D’Huyvetter M, Raes G, Goyvaerts C, Keyaerts M, Devoogdt N, Breckpot K. Theranostics in immuno-oncology using nanobody derivatives. Theranostics. 2019;9:7772–7791. doi:10.7150/thno.34941.
   PubMed Web of Science ®Google Scholar
• Quelven I, Monteil J, Sage M, Saidi A, Mounier J, Bayout A, Garrier J, Cogne M, Durand-Panteix S. 212Pb α-radioimmunotherapy targeting CD38 in multiple myeloma: a preclinical study. J Nucl Med. 2020;61:1058–1065. doi:10.2967/jnumed.119.239491.
   PubMed Web of Science ®Google Scholar
• Chen H, Zhao L, Fu K, Lin Q, Wen X, Jacobson O, Sun L, Wu H, Zhang X, Guo Z, et al. Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy. Theranostics. 2019;9:7948–7960. doi:10.7150/thno.39203.
   PubMed Web of Science ®Google Scholar
• Patel RB, Hernandez R, Carlson P, Grudzinski J, Bates AM, Jagodinsky JC, Erbe A, Marsh IR, Arthur I, Aluicio-Sarduy E, et al. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med. 2021;13:1–18.
   Web of Science ®Google Scholar